Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer’s disease?
Dementia, or Major Neurocognitive Disorder (MND), is a general term for any disease that causes a substantial decline in at least one cognitive domain including memory, learning, executive function, and additionally, impairs an individual’s ability to perform daily tasks. Alzheimer’s disease (AD) can be divided into three stages: early-stage (mild), middle-stage (moderate), and late-stage (severe). Each phase serves to classify the development of
Lecanemab for Patients with Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial
Bayesian clinical trial designs are increasingly common; given their promotion by the US Food and Drug Administration, the future use of the Bayesian approach will only continue to increase. Innovations are possible when using the Bayesian approach
Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials
Alzheimer’s disease is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual decline in intellectual ability. The accumulation of beta-amyloid (Aβ) peptides is assessed to be one of the essential neuropathological pillars of the disorder, and its dishomeostasis plays an essential
Neuroimaging in Alzheimer’s disease for Early Diagnosis: A Comprehensive Review
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the most common cause of dementia in older adults, distinguished by neurofibrillary tangles (NFTs) and neurotic plaques formed as a result of the accumulation of amyloid-beta (Aβ) peptides, most commonly in the neocortical structures and medial temporal lobe of the brain. Advanced age is the single most significant risk factor for AD. Symptoms generally appear after the age of
Prefrontal EEG slowing, synchronization, and ERP peak latency in association with predementia stages of Alzheimer’s disease
Dementia is a group of neurodegenerative disorders that affect human cognition and behaviors, like the decline in memory, changes in personality and behavior, and impairment in reasoning and language ability. Alzheimer’s disease (AD) is the main cause of
Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer’s disease using EEG technology
Alzheimer’s disease (AD) is the leading cause of dementia, accounting for an estimated 60-80% of cases worldwide. Presently, there is no effective treatment for AD and only very limited medicines show the potential for delaying the progression of this neurodegenerative disease at its early stage. On the other hand, amnestic mild cognitive impairment